Most cancer diagnostic tools tell you what happened. We tell you what's coming.

Unravel Genomics is an AI-native precision medicine company building the intelligence layer for oncology. We develop dynamic, interpretable biomarkers that predict how a patient's tumor will respond to treatment and flag resistance before it takes hold.

Our platform is the only one combining multimodal data integration (genomics, imaging, and clinical data), continuous longitudinal monitoring, and explainable AI forecasting. Together, these capabilities move oncology from reactive care to anticipatory medicine.

Our lead product, ENDORSE bx, predicts endocrine therapy response from RNA/DNA sequencing at any breast cancer stage. It outperforms every existing biomarker method, delivers a biopsy-to-report in under 2 hours, and is validated across 5 retrospective cohorts and 2 prospective clinical trials, including a live trial at City of Hope National Medical Center.

We are built on nearly two decades of foundational research published in Nature Cancer, Nature Communications, and PNAS. Our science doesn't start from a slide deck. It starts from a deep, practitioner-level understanding of tumor evolution and treatment resistance.

We partner with health systems, pharma, and diagnostics companies to bring this intelligence into clinical practice and drug development.

→ For clinicians: predictive biomarkers and real-time decision support
→ For pharma and biotech: patient stratification, go/no-go biomarkers, and CDx co-development


Unravel Genomics

Org chart

Teams

Offices

Unravel Genomics

Org chart

Teams

Offices

Related companies